Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 145 citing articles:

Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 9, pp. 810-821
Open Access | Times Cited: 2195
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1004
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das, Douglas B. Johnson
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 864
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Rebecca Dent, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 6, pp. 556-567
Open Access | Times Cited: 402
Nanomaterial Applications in Photothermal Therapy for Cancer
Austin Doughty, Ashley R. Hoover, Elivia Layton, et al.
Materials (2019) Vol. 12, Iss. 5, pp. 779-779
Open Access | Times Cited: 379
Rheumatic immune-related adverse events from cancer immunotherapy
Leonard H. Calabrese, Cassandra Calabrese, Laura C. Cappelli
Nature Reviews Rheumatology (2018) Vol. 14, Iss. 10, pp. 569-579
Closed Access | Times Cited: 193
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Alice Tison, Soizic Garaud, Laurent Chiche, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 11, pp. 641-656
Closed Access | Times Cited: 100
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Karen A. Autio, Valentina Boni, Rachel Humphrey, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 5, pp. 984-989
Open Access | Times Cited: 140
Limitations of Anti-Angiogenic Treatment of Tumors
Doménico Ribatti, Tiziana Annese, Simona Ruggieri, et al.
Translational Oncology (2019) Vol. 12, Iss. 7, pp. 981-986
Open Access | Times Cited: 109
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
Nora Möhn, Gernot Beutel, Ralf Gutzmer, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 11, pp. 1777-1777
Open Access | Times Cited: 107
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
Milena Tocut, Ronen Brenner, Gisele Zandman‐Goddard
Autoimmunity Reviews (2018) Vol. 17, Iss. 6, pp. 610-616
Closed Access | Times Cited: 100
Cutaneous adverse events caused by immune checkpoint inhibitors
Henry T. Quach, Douglas B. Johnson, Nicole R. LeBoeuf, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 4, pp. 956-966
Closed Access | Times Cited: 90
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Tim F. Greten, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 9, pp. e002794-e002794
Open Access | Times Cited: 63
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3798-3798
Open Access | Times Cited: 43
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
Carly C. Barron, Isabella Stefanova, Yevin Cha, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 8, pp. e006500-e006500
Open Access | Times Cited: 34
Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Racheli Birnboim-Perach, Itai Benhar
International Journal of Biological Sciences (2024) Vol. 20, Iss. 10, pp. 3911-3922
Open Access | Times Cited: 10
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies
Sarah Soussan, Guilhem Pupier, Isabelle Cremer, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management
Adriana T. Lopez, Larisa J. Geskin
The Oncologist (2018) Vol. 23, Iss. 10, pp. 1119-1126
Open Access | Times Cited: 79
Immune checkpoint receptors: homeostatic regulators of immunity
Antonio Riva, Shilpa Chokshi
Hepatology International (2018) Vol. 12, Iss. 3, pp. 223-236
Open Access | Times Cited: 62
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
Antonia Dimitrakopoulou-Strauß
Cancer Immunology Immunotherapy (2018) Vol. 68, Iss. 5, pp. 813-822
Closed Access | Times Cited: 59
An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, et al.
Oral Diseases (2019) Vol. 26, Iss. 3, pp. 511-526
Closed Access | Times Cited: 57
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Agnese Paderi, Roberta Giorgione, Elisa Giommoni, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 860-860
Open Access | Times Cited: 48
Immunotherapy Treatment for Triple Negative Breast Cancer
Elizabeth R. Berger, Tristen Park, Angeleke Saridakis, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 763-763
Open Access | Times Cited: 43
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Wolf H. Fridman, Sophie Sibéril, Guilhem Pupier, et al.
Seminars in Immunology (2022) Vol. 65, pp. 101703-101703
Open Access | Times Cited: 36
Antitumor Potential of Immunomodulatory Natural Products
Genoveffa Nuzzo, Giuseppina Senese, Carmela Gallo, et al.
Marine Drugs (2022) Vol. 20, Iss. 6, pp. 386-386
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top